Business Context and Reporting Period
Company: Akebia Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2024
Context: The filing announces that the Company's President and CEO, John P. Butler, will present preliminary unaudited financial results at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The presentation includes data for the fiscal year ended December 31, 2023.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notice that this information is contained in an attached presentation (Exhibit 99.1) which is incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
- Revenue: Preliminary unaudited net product revenue for Auryxia® (cumulative and for fiscal year 2023) is referenced but not quantified in this text.
- Profit/Cash Flow/Debt: No specific figures are provided in the filing text.
Material Changes
The filing does not detail specific material changes in financial performance versus prior periods within the text body. It indicates that the presentation to be delivered will contain the comparative data for the fiscal year ended December 31, 2023.
Guidance, Outlook, and Risks
Management Commentary: The Company plans to present the attached information at various investor and analyst meetings beginning January 8, 2024, coinciding with the J.P. Morgan Healthcare Conference.
Legal Disclaimers:
- The information in this 8-K (including the presentation) is not deemed "filed" for purposes of Section 18 of the Exchange Act.
- The Company makes no admission as to the materiality of the information.
- The Company undertakes no duty or obligation to update or revise the information, though it may do so at management's discretion.
Investor Verification Checklist
- Verify the specific preliminary unaudited net product revenue figures for Auryxia® by reviewing Exhibit 99.1 (the Presentation) attached to this filing.
- Confirm the full fiscal year 2023 financial results once the Company files its official Form 10-K, as this 8-K contains only preliminary data.
- Review the presentation for any updated guidance or operational milestones discussed at the J.P. Morgan Healthcare Conference.